HTLV-1 infected T cells cause bone loss via small extracellular vesicles.
Pokhrel NK, Panfil AR, Habib H, Seeniraj S, Joseph A, Rauch D, Cox L, Sprung R, Gilmore PE, Zhang Q, Townsend RR, Yu L, Yilmaz AS, Aurora R, Park W, Ratner L, Weilbaecher KN, Veis DJ.
J Extracell Vesicles. 2024 Oct;13(10):e12516. doi: 10.1002/jev2.12516.
Bisphosphonate nephrotoxicity.
Perazella MA, Markowitz GS.
Kidney Int. 2008 Dec;74(11):1385-93. doi: 10.1038/ki.2008.356. Epub 2008 Aug 6.
Animal Models of Cancer-Associated Hypercalcemia.
Kohart NA, Elshafae SM, Breitbach JT, Rosol TJ.
Vet Sci. 2017 Apr 13;4(2):21. doi: 10.3390/vetsci4020021.
Hypercalcemia of malignancy.
Insogna KL, Broadus AE.
Annu Rev Med. 1987;38:241-56. doi: 10.1146/annurev.me.38.020187.001325.
Molecular Regulation of Bone Metastasis Pathogenesis.
Wu MY, Li CJ, Yiang GT, Cheng YL, Tsai AP, Hou YT, Ho YC, Hou MF, Chu PY.
Cell Physiol Biochem. 2018;46(4):1423-1438. doi: 10.1159/000489184. Epub 2018 Apr 18.
[Treatment of malignancy associated hypercalcemia].
Tai N, Inoue D.
Clin Calcium. 2014 Aug;24(8):1223-8.
Clodronate news of efficacy in osteoporosis.
Nardi A, Ventura L, Cozzi L, Tonini G.
Clin Cases Miner Bone Metab. 2016 Jan-Apr;13(1):33-5. doi: 10.11138/ccmbm/2016.13.1.033. Epub 2016 May 11.
[Bone and calcium metabolism associated with malignancy. Malignancy-associated hypercalcemia.].
Tai N, Inoue D.
Clin Calcium. 2018;28(11):1503-1508.
Parathyroid hormone-related protein in hypercalcemia associated with hematological malignancy.
Firkin F, Schneider H, Grill V.
Leuk Lymphoma. 1998 May;29(5-6):499-506. doi: 10.3109/10428199809050909.
Overview of cancer-related hypercalcemia: epidemiology and etiology.
Muggia FM.
Semin Oncol. 1990 Apr;17(2 Suppl 5):3-9.
